Connection

Laurent Peyrin-Biroulet to Crohn Disease

Back to Details
This is a "connection" page, showing publications Laurent Peyrin-Biroulet has written about Crohn Disease.
Laurent Peyrin-Biroulet
Connection Strength
10.043
Crohn Disease
  1. Will COVID-19 Infection be Less Severe in Ulcerative Colitis Than in Crohn's Patients, Due to a Lower Rate of Smokers? J Crohns Colitis. 2020 Nov 07; 14(11):1648.
    View in: PubMed
    Score: 0.444
  2. Timely Use of Biologics in Early Crohn's Disease: The Return of "Hit Hard and Early"? Dig Dis Sci. 2019 11; 64(11):3035-3037.
    View in: PubMed
    Score: 0.414
  3. Personalised medicine in inflammatory bowel diseases: a patient survey. Scand J Gastroenterol. 2019 01; 54(1):135.
    View in: PubMed
    Score: 0.392
  4. Bispecific antibodies: The next generation of targeted inflammatory bowel disease therapies. Autoimmun Rev. 2019 Feb; 18(2):123-128.
    View in: PubMed
    Score: 0.390
  5. Accuracy of Diffusion-weighted Magnetic Resonance Imaging in Detecting Mucosal Healing and Treatment Response, and in Predicting Surgery, in Crohn's Disease. J Crohns Colitis. 2018 Nov 09; 12(10):1180-1190.
    View in: PubMed
    Score: 0.387
  6. Dose de-escalation to adalimumab 40 mg every three weeks in patients with inflammatory bowel disease-A multicenter, retrospective, observational study. Dig Liver Dis. 2019 02; 51(2):236-241.
    View in: PubMed
    Score: 0.387
  7. Cost savings using a test-based de-escalation strategy for patients with Crohn's disease in remission on optimized infliximab: A discrete event model study. Dig Liver Dis. 2019 01; 51(1):112-119.
    View in: PubMed
    Score: 0.382
  8. Diffusion-weighted MRI in inflammatory bowel disease. Lancet Gastroenterol Hepatol. 2018 06; 3(6):433-443.
    View in: PubMed
    Score: 0.375
  9. Identification of Endpoints for Development of Antifibrosis Drugs for Treatment of Crohn's Disease. Gastroenterology. 2018 07; 155(1):76-87.
    View in: PubMed
    Score: 0.371
  10. Early changes in the pharmacokinetic profile of vedolizumab-treated patients with IBD may predict response after dose optimisation. Gut. 2019 01; 68(1):178-179.
    View in: PubMed
    Score: 0.365
  11. Positioning Ustekinumab in Crohn's Disease: From Clinical Evidence to Clinical Practice. J Crohns Colitis. 2017 Oct 01; 11(10):1258-1266.
    View in: PubMed
    Score: 0.358
  12. Adherence to infliximab therapy in inflammatory bowel disease patients in a real-life setting. J Dig Dis. 2017 Oct; 18(10):566-573.
    View in: PubMed
    Score: 0.358
  13. Management of patients with inflammatory bowel disease and spondyloarthritis. Expert Rev Clin Pharmacol. 2017 Dec; 10(12):1363-1374.
    View in: PubMed
    Score: 0.358
  14. Early intervention in Crohn's disease: towards disease modification trials. Gut. 2017 12; 66(12):2179-2187.
    View in: PubMed
    Score: 0.357
  15. Treatment Persistence for Infliximab Versus Adalimumab in Crohn's Disease: A 14-Year Single-Center Experience. Inflamm Bowel Dis. 2017 06; 23(6):976-985.
    View in: PubMed
    Score: 0.350
  16. Value of cross-sectional imaging in assessing active Crohn's disease before stoma reversal. Dig Liver Dis. 2017 Aug; 49(8):864-871.
    View in: PubMed
    Score: 0.347
  17. Review article: moving towards common therapeutic goals in Crohn's disease and rheumatoid arthritis. Aliment Pharmacol Ther. 2017 04; 45(8):1058-1072.
    View in: PubMed
    Score: 0.344
  18. French national consensus clinical guidelines for the management of Crohn's disease. Dig Liver Dis. 2017 Apr; 49(4):368-377.
    View in: PubMed
    Score: 0.340
  19. Mesenteric fat as a source of C reactive protein and as a target for bacterial translocation in Crohn's disease. Gut. 2012 Jan; 61(1):78-85.
    View in: PubMed
    Score: 0.236
  20. Inflammatory Bowel Disease Management During the Coronavirus-19 Outbreak: A Survey From the European Crohn's and Colitis Organization. Gastroenterology. 2020 Jul; 159(1):14-19.e3.
    View in: PubMed
    Score: 0.107
  21. Oral Curcumin No More Effective Than Placebo in Preventing Recurrence of Crohn's Disease After Surgery in a Randomized Controlled Trial. Clin Gastroenterol Hepatol. 2020 06; 18(7):1553-1560.e1.
    View in: PubMed
    Score: 0.102
  22. Challenges in the Pathophysiology, Diagnosis, and Management of Intestinal Fibrosis in Inflammatory Bowel Disease. Gastroenterology. 2022 01; 162(1):26-31.
    View in: PubMed
    Score: 0.101
  23. Environmental Risk Factors for Inflammatory Bowel Diseases: An Umbrella Review of Meta-analyses. Gastroenterology. 2019 09; 157(3):647-659.e4.
    View in: PubMed
    Score: 0.100
  24. Noninvasive Multimodal Methods to Differentiate Inflamed vs Fibrotic Strictures in Patients With Crohn's Disease. Clin Gastroenterol Hepatol. 2019 11; 17(12):2397-2415.
    View in: PubMed
    Score: 0.100
  25. Vedolizumab for the treatment of inflammatory bowel diseases: from symptomatic control to mucosal healing. Immunotherapy. 2019 05; 11(7):565-575.
    View in: PubMed
    Score: 0.099
  26. Comparative Accuracy of Bowel Ultrasound Versus Magnetic Resonance Enterography in Combination With Colonoscopy in Assessing Crohn's Disease and Guiding Clinical Decision-making. J Crohns Colitis. 2018 Nov 15; 12(11):1280-1287.
    View in: PubMed
    Score: 0.097
  27. Effectiveness and Safety of Vedolizumab in Anti-TNF-Naïve Patients With Inflammatory Bowel Disease-A Multicenter Retrospective European Study. Inflamm Bowel Dis. 2018 10 12; 24(11):2442-2451.
    View in: PubMed
    Score: 0.096
  28. Anti-TNF therapy for genital fistulas in female patients with Crohn's disease: a nationwide study from the Groupe d'Etude Thérapeutique des Affections Inflammatoires du tube Digestif (GETAID). Aliment Pharmacol Ther. 2018 10; 48(8):831-838.
    View in: PubMed
    Score: 0.096
  29. PF-00547659 for the treatment of Crohn's disease and ulcerative colitis. Expert Opin Investig Drugs. 2018 Jul; 27(7):623-629.
    View in: PubMed
    Score: 0.095
  30. Post-operative complications in elderly onset inflammatory bowel disease: a population-based study. Aliment Pharmacol Ther. 2018 06; 47(12):1652-1660.
    View in: PubMed
    Score: 0.093
  31. Heterogeneity in Definitions of Efficacy and Safety Endpoints for Clinical Trials of Crohn's Disease: A Systematic Review. Clin Gastroenterol Hepatol. 2018 09; 16(9):1407-1419.e22.
    View in: PubMed
    Score: 0.093
  32. Prolonged azathioprine treatment reduces the need for surgery in early Crohn's disease. J Gastroenterol Hepatol. 2018 Mar; 33(3):664-670.
    View in: PubMed
    Score: 0.092
  33. Vedolizumab for the treatment of Crohn's disease. Expert Rev Clin Immunol. 2018 03; 14(3):179-189.
    View in: PubMed
    Score: 0.092
  34. Long-term efficacy and safety of ustekinumab in 122 refractory Crohn's disease patients: a multicentre experience. Aliment Pharmacol Ther. 2018 03; 47(5):588-595.
    View in: PubMed
    Score: 0.091
  35. Increasing Infliximab Dose Based on Symptoms, Biomarkers, and Serum Drug Concentrations Does Not Increase Clinical, Endoscopic, and Corticosteroid-Free Remission in Patients With Active Luminal Crohn's Disease. Gastroenterology. 2018 04; 154(5):1343-1351.e1.
    View in: PubMed
    Score: 0.091
  36. High Risk of Anal and Rectal Cancer in Patients With Anal and/or Perianal Crohn's Disease. Clin Gastroenterol Hepatol. 2018 06; 16(6):892-899.e2.
    View in: PubMed
    Score: 0.091
  37. Long-term safety of adalimumab in clinical trials in adult patients with Crohn's disease or ulcerative colitis. Aliment Pharmacol Ther. 2018 01; 47(2):219-228.
    View in: PubMed
    Score: 0.090
  38. Systematic review and meta-analysis: assessment of factors affecting disability in inflammatory bowel disease and the reliability of the inflammatory bowel disease disability index. Aliment Pharmacol Ther. 2018 Jan; 47(1):6-15.
    View in: PubMed
    Score: 0.090
  39. Effectiveness of Mesalazine, Thiopurines and Tumour Necrosis Factor Antagonists in Preventing Post-Operative Crohn's Disease Recurrence in a Real-Life Setting. Digestion. 2017; 96(3):166-172.
    View in: PubMed
    Score: 0.089
  40. Dramatic Increase in Incidence of Ulcerative Colitis and Crohn's Disease (1988-2011): A Population-Based Study of French Adolescents. Am J Gastroenterol. 2018 02; 113(2):265-272.
    View in: PubMed
    Score: 0.089
  41. Indicators of suboptimal tumor necrosis factor antagonist therapy in inflammatory bowel disease. Dig Liver Dis. 2017 Oct; 49(10):1086-1091.
    View in: PubMed
    Score: 0.089
  42. One-year effectiveness and safety of vedolizumab therapy for inflammatory bowel disease: a prospective multicentre cohort study. Aliment Pharmacol Ther. 2017 08; 46(3):310-321.
    View in: PubMed
    Score: 0.088
  43. Is Mesalamine Effective for the Induction of Remission in Crohn's Disease? Inflamm Bowel Dis. 2017 05; 23(5):E22-E23.
    View in: PubMed
    Score: 0.087
  44. Cost-utility of biological treatment sequences for luminal Crohn's disease in Europe. Expert Rev Pharmacoecon Outcomes Res. 2017 Dec; 17(6):597-606.
    View in: PubMed
    Score: 0.087
  45. Systematic review with meta-analysis: comparative efficacy of biologics for induction and maintenance of mucosal healing in Crohn's disease and ulcerative colitis controlled trials. Aliment Pharmacol Ther. 2017 May; 45(10):1291-1302.
    View in: PubMed
    Score: 0.086
  46. Systematic review with meta-analysis: use of 5-aminosalicylates and risk of colorectal neoplasia in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2017 05; 45(9):1179-1192.
    View in: PubMed
    Score: 0.086
  47. IBD immunopathogenesis: A comprehensive review of inflammatory molecules. Autoimmun Rev. 2017 Apr; 16(4):416-426.
    View in: PubMed
    Score: 0.086
  48. Efficacy of adalimumab in patients with Crohn's disease and symptomatic small bowel stricture: a multicentre, prospective, observational cohort (CREOLE) study. Gut. 2018 01; 67(1):53-60.
    View in: PubMed
    Score: 0.085
  49. Development and Internal Validation of a Model Using Fecal Calprotectin in Combination with Infliximab Trough Levels to Predict Clinical Relapse in Crohn's Disease. Inflamm Bowel Dis. 2017 01; 23(1):126-132.
    View in: PubMed
    Score: 0.085
  50. The Crohn's Disease-Ulcerative Colitis Clinical Appraisal Update: Emerging Trends in Clinical Practice. Clin Gastroenterol Hepatol. 2016 09; 14(9):e121-2.
    View in: PubMed
    Score: 0.083
  51. Validation of the Inflammatory Bowel Disease Disability Index in a population-based cohort. Gut. 2017 04; 66(4):588-596.
    View in: PubMed
    Score: 0.079
  52. Treatment of fibrostenotic and fistulizing Crohn's disease. Digestion. 2012; 86 Suppl 1:23-7.
    View in: PubMed
    Score: 0.063
  53. Metagenomic analysis of intestinal mucosa revealed a specific eukaryotic gut virome signature in early-diagnosed inflammatory bowel disease. Gut Microbes. 2019; 10(2):149-158.
    View in: PubMed
    Score: 0.024
  54. Impact of vedolizumab therapy on extra-intestinal manifestations in patients with inflammatory bowel disease: a multicentre cohort study nested in the OBSERV-IBD cohort. Aliment Pharmacol Ther. 2018 02; 47(4):485-493.
    View in: PubMed
    Score: 0.023
  55. Frequency of and Factors Associated With Sexual Dysfunction in Patients With Inflammatory Bowel Disease. J Crohns Colitis. 2017 Oct 27; 11(11):1347-1352.
    View in: PubMed
    Score: 0.023
  56. Incidence and Phenotype at Diagnosis of Very-early-onset Compared with Later-onset Paediatric Inflammatory Bowel Disease: A Population-based Study [1988-2011]. J Crohns Colitis. 2017 May 01; 11(5):519-526.
    View in: PubMed
    Score: 0.022
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.